In an unexpected development, Novartis (NVS) and Amgen (AMGN) filed competing lawsuits over a potentially lucrative relationship to jointly develop and market Aimovig, a new type of migraine treatment that some Wall Street analysts expect will become a multi-billion-dollar market.

The trigger for the dispute was a deal between Sandoz, the generic unit at Novartis, which agreed to do contract manufacturing work for Alder BioPharmaceuticals, which is developing its own migraine treatment. Amgen contended the deal breached its contract with Novartis, while Novartis argued Amgen is using this as a “pretext” to keep Aimovig profits for itself.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy